Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT02340156
Title Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors SynerGene Therapeutics, Inc.
Age Groups: adult
Covered Countries USA

No variant requirements are available.